NASDAQ$GH
Guardant Health Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Guardant Health experienced revenue growth, driven by increased clinical and biopharma testing volume, while also managing operating expenses and making progress with FDA submissions.
Guardant Health reported a 22% increase in revenue for Q4 2023, reaching $155.1 million, driven by growth in clinical and biopharmaceutical testing volumes. The company is progressing with FDA submissions for its Shield IVD test and anticipates a pivotal year for its screening business in 2024.
- Revenue increased by 22% to $155.1 million compared to Q4 2022.
- Precision oncology revenue grew by 25%, driven by increased clinical and biopharma testing volume.
- Clinical tests to customers increased by 29% and biopharmaceutical tests increased by 16% compared to the prior year period.
- Ended the year with $1.2 billion in cash, cash equivalents and marketable debt securities.
Headline financials
Revenue & EPS history
Guardant Health · Revenue · Quarterly
$155M
Revenue by segment
Guardant Health · $133M total across 1 segment · Q3 2023
- Oncology Revenue$133M+30.7%100.0%
Forward guidance
Guardant Health anticipates full year 2024 revenue to be in the range of $655 to $670 million, representing growth of 16% to 19% compared to full year 2023.
Tailwinds
- Full year 2024 revenue excluding screening to be in the range of $655 to $670 million, representing growth of 16% to 19% compared to full year 2023.
- Full year 2024 non-GAAP gross margin excluding screening to be in the range of 60% to 62%.
- Total non-GAAP operating expenses to be in the range of $740 to $750 million, representing a 1% to 3% increase compared to full year 2023.
- Free cash flow to be in the range of negative $320 to $330 million in 2024, an improvement compared to the full year 2023.
- Improved ASPs with Guardant360 LDT CMS reimbursement increased from $3,500 to $5,000 effective January 1, 2024
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+3.8%
Avg return
Earnings day
+2.6%
Avg return
5 days after
+3.9%
Avg return
30 days after
60%
18 / 30 earnings
Positive
+41.3%
Q4 2018
Best reaction
-30.0%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.3% | +6.6% | +36.1% | |
| Q4 2025 | -3.0% | -10.4% | -19.9% | |
| Q3 2025 | +28.5% | +35.8% | +50.0% | |
| Q1 2025 | +3.5% | -11.2% | -14.0% | |
| Q4 2024 | -9.6% | -8.9% | -2.7% | |
| Q3 2024 | +21.6% | +24.8% | +56.8% | |
| Q2 2024 | -5.9% | -5.3% | -26.2% | |
| Q1 2024 | +20.0% | +32.7% | +53.8% | |
| Q4 2023 | -14.3% | -13.8% | -23.9% | |
| Q3 2023 | -8.5% | -24.7% | -10.2% | |
| Q2 2023 | +4.6% | +1.9% | -3.1% | |
| Q1 2023 | +17.2% | +12.1% | +38.5% | |
| Q4 2022 | +4.4% | +11.7% | -12.6% | |
| Q3 2022 | +3.3% | -3.1% | +17.5% | |
| Q2 2022 | +1.6% | -6.0% | +2.0% | |
| Q1 2022 | -30.0% | -44.3% | -32.3% | |
| Q4 2021 | +6.0% | +7.0% | -4.3% | |
| Q3 2021 | -3.8% | -5.8% | -20.8% | |
| Q2 2021 | +0.2% | -7.7% | +15.7% | |
| Q1 2021 | -3.1% | -14.0% | -15.8% | |
| Q4 2020 | -6.7% | -5.0% | -15.3% | |
| Q3 2020 | -0.4% | -1.1% | +9.0% | |
| Q2 2020 | +0.6% | -4.0% | +6.8% | |
| Q1 2020 | +9.0% | +19.6% | +2.9% | |
| Q4 2019 | -14.7% | -2.1% | -25.9% | |
| Q3 2019 | +11.2% | +13.8% | +14.4% | |
| Q2 2019 | +25.8% | +18.2% | -5.2% | |
| Q1 2019 | +17.4% | +12.0% | +40.3% | |
| Q4 2018 | +41.3% | +46.6% | +7.9% | |
| Q3 2018 | -6.7% | +3.1% | -2.7% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro